<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345291</url>
  </required_header>
  <id_info>
    <org_study_id>NRD135S.E1-201</org_study_id>
    <nct_id>NCT02345291</nct_id>
  </id_info>
  <brief_title>Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients</brief_title>
  <official_title>A Phase 2a, Randomized, Double-blind, Placebo (Vehicle)-Controlled, Dose Finding Trial to Assess the Safety, Tolerability and Efficacy of NRD135S.E1 in Patients With Neuropathic Pain Associated With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novaremed Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novaremed Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, Phase 2a, randomized, double-blind, placebo (vehicle)-controlled,&#xD;
      parallel-group, dose-finding study designed to evaluate the efficacy, safety and tolerability&#xD;
      of NRD135S.E1 in adult patients with diabetes mellitus type 1 or 2 with neuropathic pain.&#xD;
      Potential study patients will sign informed consent prior to undergoing any study-related&#xD;
      procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following screening, eligible patients will be enrolled and go through a week of washout of&#xD;
      analgesic treatment. Patients who are still eligible following the washout will be randomized&#xD;
      to one of four treatment groups: NRD135S.E1 at 10, 40, or 150 mg per day or placebo&#xD;
      (vehicle).&#xD;
&#xD;
      All four treatment groups will start study treatment with 1 week of single blind placebo&#xD;
      (baseline week) followed by 3 weeks of the allocated double blind treatment (Weeks 1, 2, and&#xD;
      3). All patients will be followed for 30 days after the last study drug administration. The&#xD;
      total study duration per patient is 9 to10 weeks.&#xD;
&#xD;
      Visit schedule: Screening (Days minus 14 to minus 8, Visit 1). Washout visit (Day minus 7,&#xD;
      Visit 2). Randomization and start of placebo treatment (Day 1, Visit 3). Double blind&#xD;
      treatment visits on Days 8 (Visit 4), 15 (Visit 5) and 29 (Visit 6). Follow up visit by&#xD;
      telephone (Day 59, Visit 7).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Change from the baseline week to Week 3 in the weekly average daily pain intensity as measured on an 11-point numerical pain scale (NPS)</measure>
    <time_frame>three weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline week to Week 3 in the weekly maximum daily pain intensity as measured on the NPS</measure>
    <time_frame>three weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline week to Week 3 in the weekly consumption of rescue analgesic (i.e., number of paracetamol 500 mg tablets taken per week)</measure>
    <time_frame>three weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change from Day 8 (end of baseline week) to Day 29 (24 h after last study drug administration) in Short-Form McGill Pain Questionnaire (SF-MPQ) score</measure>
    <time_frame>three</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician's Global Impression of Change from the baseline week at Day 29 (24 h after last study drug administration)</measure>
    <time_frame>three weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impression of Change from the baseline week at Day 29 (24 h after last study drug administration)</measure>
    <time_frame>three weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline week to Week 3 in the weekly Daily Sleep Interference Score</measure>
    <time_frame>three weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent AEs (TEAEs)</measure>
    <time_frame>three weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Diabetic Peripheral Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>NRD135S.E1 A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A = 10 mg NRD135S.E1 once daily PO for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRD135S.E1 B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B = 40 mg NRD135S.E1 once daily PO for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRD135S.E1 C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C = 150 mg NRD135S.E1 once daily PO for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match NRD135S.E1 D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>D = Placebo once daily PO for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRD135S.E1</intervention_name>
    <description>A small chemical entity for treatment of neuropathic pain NRD135S.E1</description>
    <arm_group_label>NRD135S.E1 A</arm_group_label>
    <arm_group_label>NRD135S.E1 B</arm_group_label>
    <arm_group_label>NRD135S.E1 C</arm_group_label>
    <other_name>E1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match NRD135S.E1</intervention_name>
    <description>Placebo capsule to match NRD135S.E1 capsules</description>
    <arm_group_label>Placebo to match NRD135S.E1 D</arm_group_label>
    <other_name>Placebo for E1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. -Males agree to use condoms throughout treatment and follow up study periods.&#xD;
&#xD;
               -  Females must not be of childbearing potential as evidenced by at least one of the&#xD;
                  following:&#xD;
&#xD;
                  ≥ 62 years old and amenorrheic for ≥ 1 year&#xD;
&#xD;
               -  Amenorrheic ≥ 12 consecutive months and a documented serum follicle stimulating&#xD;
                  hormone (FSH) level &gt; 35 mIU/mL&#xD;
&#xD;
               -  Irregular menstrual periods and a documented FSH level &gt; 35 mIU/mL&#xD;
&#xD;
               -  On hormone replacement therapy and prior clinical evidence of menopause based on&#xD;
                  any of the criteria above&#xD;
&#xD;
               -  Surgically sterile&#xD;
&#xD;
          2. Known stable diabetes mellitus for the last 3 months. (No oral hypoglycemic&#xD;
             medications change allowed. Maximum insulin change allowed is ± 20%).&#xD;
&#xD;
          3. Evidence of peripheral neuropathy associated with diabetes mellitus diagnosed by DN4&#xD;
             criteria.&#xD;
&#xD;
          4. Presence of ongoing pain due to DPN for at least 3 months.&#xD;
&#xD;
          5. Mean DPN pain intensity of 4 to 9 on the NPS at screening.&#xD;
&#xD;
          6. HbA1c ≤ 9% of total hemoglobin at screening.&#xD;
&#xD;
          7. Willing to stop pain medications for DPN (except for limited use of paracetamol).&#xD;
&#xD;
          8. Signed written informed consent.&#xD;
&#xD;
               -  Subjects must have signed and dated an Institutional Review Board / Independent&#xD;
                  Ethics Committee approved written informed consent form in accordance with&#xD;
                  regulatory and institutional guidelines. This must be obtained before the&#xD;
                  performance of any protocol related procedures that are not part of normal&#xD;
                  subject care.&#xD;
&#xD;
               -  Subjects must be willing and able to comply with scheduled visits, treatment&#xD;
                  schedule, laboratory testing, and other requirements of the study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Female of childbearing potential.&#xD;
&#xD;
          2. Neurologic disorders unrelated to DPN that may interfere with the assessment of DPN.&#xD;
&#xD;
          3. Known allergy or intolerance to paracetamol.&#xD;
&#xD;
          4. Evidence of non-DPN polyneuropathy.&#xD;
&#xD;
          5. The presence of severe pain associated with conditions other than DPN (e.g.,&#xD;
             peripheral vascular disease, phantom pain, etc.) that could confound the&#xD;
             self-evaluation of pain due to DPN.&#xD;
&#xD;
          6. Any anti-epileptic or anti-depressive treatment. Amityptiline (Elatrol/Elatrolet) or&#xD;
             duloxetine (Cymbalta) are permitted at screening but not later.&#xD;
&#xD;
          7. Constant use of non-steroidal anti-inflammatory drugs or opiates that cannot be&#xD;
             withdrawn during the washout period and the whole study duration.&#xD;
&#xD;
          8. Participation in another clinical trial in the last 3 months.&#xD;
&#xD;
          9. Poor compliance with prescribed medication or alcohol or drug abuse within 2 years&#xD;
             before screening.&#xD;
&#xD;
         10. Hypersensitivity to paracetamol or any of the inactive ingredients in NRD135S.E1&#xD;
             capsules.&#xD;
&#xD;
         11. Any serious medical condition, including the presence of laboratory abnormalities,&#xD;
             that places the patient at an unacceptable risk if he or she participates in this&#xD;
             study or confounds the ability to interpret data from the study.&#xD;
&#xD;
         12. Patients with any hematological disorder.&#xD;
&#xD;
         13. Prisoners or subjects who are involuntarily incarcerated.&#xD;
&#xD;
         14. Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (e.g. infectious disease) illness.&#xD;
&#xD;
         15. Patients whose judgment has been impaired by their physical ir mental condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eli Kaplan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novaremed Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes and Endocrinology clinic, Bat-Yamon Medical center, Clalit health services</name>
      <address>
        <city>Bat-Yam</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes clinic, Lin Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>35152</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center, Diabetic Endocrine unit</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetic and Endocrinology clinic, Clalit health services</name>
      <address>
        <city>Jerusalem</city>
        <zip>9310609</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center, Endocrynology, diabetes and metabolism Unit</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44821</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Department Migdal Hamea Clalit health services</name>
      <address>
        <city>Tel Aviv</city>
        <zip>62038</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DMC Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>6937947</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sorasky Medical Center, Diabetic unit</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziv Medical Center, Endocrinology Unit</name>
      <address>
        <city>Zefat</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>January 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>February 19, 2017</submitted>
    <returned>April 4, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

